J&J Unit Fights Use Of New Topamax Label In Defect Suits
By Matt Fair ( March 5, 2014, 2:05 PM EST) -- A Johnson & Johnson unit said Tuesday that plaintiffs in a cluster of suits alleging that the anti-epilepsy drug Topamax caused birth defects had improperly asked a Pennsylvania judge to reconsider a decision over the admissibility of a 2011 label change strengthening warnings about risks to pregnant women....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.